 Secondary Endpoints: 1 Measures of HIV disease progression, including CD4 change, time to ART initiation, and mean plasma VL change from baseline to 6 and through 24 months among pre-ART women. 2 Hemoglobin change and incidence of STIs and PID for all participants through 24 months. 3 IUD continuation and expulsion rates between study arms comparing different IUDs over a 24-month period and acceptability measures through quantitative and qualitative methods. 4 Comparison of female genital tract sampling methods for recovery of HIV RNA as measured by VL and immune mediators e.g. cytokines. 